Filing Flows

Filing Flows › Vivos Therapeutics (VVOS) › How it makes money

How Vivos Therapeutics (VVOS) makes money

Vivos Therapeutics (VVOS) made $5.2M of revenue in the second quarter 2026 (Q2 2026), +165% from a year earlier. Service brought in $3.8M (74%); Product brought in $1.4M (26%).

Drawing the Sankey…

Vivos Therapeutics revenue by segment, Q2 2026Vivos Therapeutics revenue by segment, Q2 2026Service$3.8MProduct$1.4M
Vivos Therapeutics: revenue by line, Q4 2024 to Q2 2026Vivos Therapeutics: revenue by line, Q4 2024 to Q2 2026ServiceProductService: $3.8M latest$3.8MProduct: $1.4M latest$1.4MQ4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Product went from 61% of revenue in Q4 2024 to 26% in Q2 2026, the largest shift in the mix.
Vivos Therapeutics revenue by quarterVivos Therapeutics revenue by quarter$3.7MQ4 2024$3.0MQ1 2025$3.8MQ2 2025$6.8MQ3 2025$3.8MQ4 2025$5.1MQ1 2026$5.2MQ2 2026

Revenue by segment, Q2 2026

SegmentRevenueShareQ/QY/Y
Service$3.8M73.7%+5%—
  ↳ Sleep Testing Services$2.4M46.4%+4%+183%
  ↳ Treatment Centers$767K14.9%-14%—
  ↳ Appliances$640K12.4%+52%-38%
Product$1.4M26.3%-12%-30%
  ↳ Tooth Positioners$715K13.9%-30%-17%
  ↳ Myofunctional Therapy Services$337K6.5%+170%+107%
  ↳ Sponsorship Seminar Other$161K3.1%-21%-74%
  ↳ Billing Intelligence Services$129K2.5%-11%-32%
  ↳ VIP$12K0.2%-68%-91%

Where each dollar of revenue goes

LineQ2 2026% of revenue
Revenue$5.2M100.0%

Revenue, quarter by quarter

QuarterRevenueY/Y
Q2 2026$5.2M+35%
Q1 2026$5.1M+70%
Q4 2025$3.8M+3%
Q3 2025$6.8M+76%
Q2 2025$3.8M-6%
Q1 2025$3.0M-12%
Q4 2024$3.7M+14%

From Vivos Therapeutics' 10-Q filed Aug 14, 2026 (on EDGAR).

Questions

How does Vivos Therapeutics make money?

Vivos Therapeutics (VVOS) made $5.2M of revenue in the second quarter 2026 (Q2 2026), +165% from a year earlier. Service brought in $3.8M (74%); Product brought in $1.4M (26%).

What is Vivos Therapeutics' biggest business?

Service: $3.8M in the second quarter 2026, 74% of revenue.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.